Ryan D. Maynard - 10 Jun 2022 Form 4 Insider Report for IOVANCE BIOTHERAPEUTICS, INC. (IOVA)

Reporting relationship: Director
Issuer ticker: IOVA
Reported as of: 10 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Jun 2022, 17:02:42 UTC
Prior SEC filing: 02 Jun 2022
Next SEC filing: 14 Sep 2022
Source filing: View source filing
Reporting owner signature: /s/ Ryan Maynard

Key filing fact

Ryan D. Maynard filed Form 4 for IOVANCE BIOTHERAPEUTICS, INC. (IOVA) on 14 Jun 2022.

Key facts

This page summarizes Ryan D. Maynard's Form 4 filing for IOVANCE BIOTHERAPEUTICS, INC. (IOVA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 14 Jun 2022, 17:02.

Change

Previous filing in this sequence was filed on 02 Jun 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IOVA transaction Derivative

Deferred Restricted Stock Unit

Award

Transaction value: $0
Shares: +51,204
Change %
Price: $0.000000
Shares after: 51,204
Date: 10 Jun 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 51,204
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended).

Footnote F2

Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (2) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date.